Back to Journals » Neuropsychiatric Disease and Treatment » Volume 4 » Issue 4

Current approaches to the treatment of Parkinson’s disease

Authors Jankovic J, Aguilar LG

Published 8 August 2008 Volume 2008:4(4) Pages 743—757

DOI https://doi.org/10.2147/NDT.S2006


Joseph Jankovic, L Giselle Aguilar

Parkinson’s Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine

Abstract: Enormous progress has been made in the treatment of Parkinson’s disease (PD). As a result of advances in experimental therapeutics, many promising therapies for PD are emerging. Levodopa remains the most potent drug for controlling PD symptoms, yet is associated with significant complications such as the “wearing off” effect, levodopa-induced dyskinesias and other motor complications. Catechol-o-methyl-transferase inhibitors, dopamine agonists and nondopaminergic therapy are alternative modalities in the management of PD and may be used concomitantly with levodopa or one another. The neurosurgical treatment, focusing on deep brain stimulation, is reviewed briefly. Although this review has attempted to highlight the most recent advances in the treatment of PD, it is important to note that new treatments are not necessarily better than the established conventional therapy and that the treatment options must be individualized and tailored to the needs of each individual patient.

Keywords: Parkinson’s disease, levodopa, medical treatment, pallidotomy, deep brain stimulation

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]